Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | DRD2 | P14416 | 7/20 | 0.65 |
| ▸ | DRD4 | P21917 | 7/20 | 0.65 |
| ▸ | DRD3 | P35462 | 6/20 | 0.65 |
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
| ▸ | HTR3A | P46098 | 1/20 | 0.59 |
| ▸ | HTR7 | P34969 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8357217 | 0.90 | ALDH1A1 (0.82) | ALDH1A1TSHRMEN1KMT2AKDM4E | |
| SCHEMBL1876523 | 0.90 | MEN1 (0.87) | ALDH1A1TSHRMEN1KMT2AKDM4E | |
| SCHEMBL8872544 | 0.88 | ALDH1A1 (0.78) | ALDH1A1TSHRMEN1KMT2AKDM4E | |
| Hydrochloric Acid SCHEMBL7972283 | 0.87 | ALDH1A1 (0.76) | ALDH1A1TSHRMEN1KMT2AKDM4E | |
| SCHEMBL13219071 | 0.85 | ALDH1A1 (0.74) | ALDH1A1TSHRKMT2AKDM4EDRD2 | |
| SCHEMBL7501326 | 0.83 | DRD2 (0.76) | ALDH1A1TSHRMEN1KMT2AKDM4E | |
| SCHEMBL5986969 | 0.83 | MEN1 (0.74) | ALDH1A1TSHRMEN1KMT2AKDM4E | |
| SCHEMBL16226080 | 0.81 | SIGMAR1 (0.78) | ALDH1A1TSHRKMT2ADRD4 | |
| SCHEMBL7508092 | 0.80 | ALDH1A1 (0.67) | ALDH1A1TSHRMEN1KMT2AKDM4E | |
| SCHEMBL12861757 | 0.80 | DRD4 (0.79) | ALDH1A1TSHRKDM4EDRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101193635-A | Multicyclic compounds and methods of their use | LEXICON GENETICS INC (US) | 2008-06-04 | — | — | CN | claimed |
| EP-1893212-A2 | MULTICYCLIC COMPOUNDS AND METHODS OF THEIR USE | Lexicon Pharmaceuticals, Inc. (US) | 2008-03-05 | — | — | EP | claimed |
| WO-2006124748-A2 | MULTICYCLIC COMPOUNDS AND METHODS OF THEIR USE | LEXICON GENETICS INCORPORATED (US) | 2006-11-23 | — | — | WO | claimed |
| US-20060258672-A1 | Multicyclic compounds and methods of their use | LEXICON PHARMACEUTICALS, INC. | 2006-11-16 | — | — | US | claimed |
| US-8772291-B2 | Multicyclic compounds and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| EP-1893212-B1 | MULTICYCLIC COMPOUNDS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2013-10-16 | — | — | EP | disclosed |
| US-20100081691-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| US-20090306100-A1 | METHODS OF TREATING SCHIZOPHRENIA | LEXICON PHARMACEUTICALS, INC. | 2009-12-10 | — | — | US | disclosed |
| EP-2089018-A2 | METHODS OF TREATING COGNITIVE IMPAIRMENT AND DEMENTIA | Lexicon Pharmaceuticals, Inc. (US) | 2009-08-19 | — | — | EP | disclosed |
| US-20080153811-A1 | methods for treating, managing and preventing cognitive impairment associated with various diseases and disorders, age-associated memory impairment, and dementia. | LEXICON PHARMACEUTICALS, INC. | 2008-06-26 | — | — | US | disclosed |
| WO-2008067121-A2 | METHODS OF TREATING COGNITIVE IMPAIRMENT AND DEMENTIA | LEXICON PHARMACEUTICALS, INC. (US) | 2008-06-05 | — | — | WO | disclosed |
| CN-101193635-A | Multicyclic compounds and methods of their use | LEXICON GENETICS INC (US) | 2008-06-04 | — | — | CN | disclosed |
| EP-1893212-A2 | MULTICYCLIC COMPOUNDS AND METHODS OF THEIR USE | Lexicon Pharmaceuticals, Inc. (US) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006124897-A2 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITION | LEXICON GENETICS INCORPORATED (US) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006124748-A2 | MULTICYCLIC COMPOUNDS AND METHODS OF THEIR USE | LEXICON GENETICS INCORPORATED (US) | 2006-11-23 | — | — | WO | disclosed |
| US-20060258691-A1 | Methods and compositions for improving cognition | LEXICON PHARMACEUTICALS, INC. | 2006-11-16 | — | — | US | disclosed |
| US-20060258672-A1 | Multicyclic compounds and methods of their use | LEXICON PHARMACEUTICALS, INC. | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081691-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF THEIR USE | GRIN2C, CHAT, COMT | ALDH1A1 1258/4885TSHR 4163/4885MEN1 1568/4885 |
| US-20080153811-A1 | methods for treating, managing and preventing cognitive impairment associated with various diseases and disorders, age-associated memory impairment, and dementia. | CHAT, PSEN2, PSEN1 | ALDH1A1 2105/4885TSHR 4433/4885MEN1 2823/4885 |
| US-20090306100-A1 | METHODS OF TREATING SCHIZOPHRENIA | CHAT, GAP43, GRIN2A | ALDH1A1 2253/4885TSHR 2746/4885MEN1 4522/4885 |
| US-20060258691-A1 | Methods and compositions for improving cognition | PSEN1, PSEN2, APP | ALDH1A1 2944/4885TSHR 4853/4885MEN1 1620/4885 |
| US-20060258672-A1 | Multicyclic compounds and methods of their use | GRIN2C, CHAT, COMT | ALDH1A1 1258/4885TSHR 4163/4885MEN1 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.